Learn about how the OncoSignature™ high throughput screening platform can be used for the prediction of anticancer drug sensitivity in this scientific poster. Our preclinical services team demonstrate the platform's applicability to drug sensitivity applications through a case study identifying predictors of sensitivity to BRAF inhibitors.
The poster has been converted into a digital-friendly layout for ease of reading.
Download to learn more and explore the data.
For research use only. Not for use in diagnostic procedures.
OncoSignature high throughput screening platform for the prediction of anticancer drug sensitivity